Neurotech International Ltd (NTI) - Net Assets

Latest as of December 2025: AU$5.88 Million AUD ≈ $4.16 Million USD

Based on the latest financial reports, Neurotech International Ltd (NTI) has net assets worth AU$5.88 Million AUD (≈ $4.16 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$6.81 Million ≈ $4.82 Million USD) and total liabilities (AU$932.85K ≈ $660.05K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NTI tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$5.88 Million
% of Total Assets	86.3%
Annual Growth Rate	9.08%
5-Year Change	-23.49%
10-Year Change	-79.6%
Growth Volatility	359.91

Neurotech International Ltd - Net Assets Trend (2015–2025)

This chart illustrates how Neurotech International Ltd's net assets have evolved over time, based on quarterly financial data. See NTI days of operational coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Neurotech International Ltd (2015–2025)

The table below shows the annual net assets of Neurotech International Ltd from 2015 to 2025. For live valuation and market cap data, see NTI market cap.

Year	Net Assets	Change
2025-06-30	AU$2.95 Million ≈ $2.09 Million	-75.17%
2024-06-30	AU$11.90 Million ≈ $8.42 Million	+200.32%
2023-06-30	AU$3.96 Million ≈ $2.80 Million	+177.06%
2022-06-30	AU$1.43 Million ≈ $1.01 Million	-62.97%
2021-06-30	AU$3.86 Million ≈ $2.73 Million	+697.48%
2020-06-30	AU$-646.29K ≈ $-457.29K	-317.30%
2019-06-30	AU$297.41K ≈ $210.44K	-92.97%
2018-06-30	AU$4.23 Million ≈ $2.99 Million	-1.49%
2017-06-30	AU$4.30 Million ≈ $3.04 Million	-70.34%
2016-06-30	AU$14.48 Million ≈ $10.25 Million	+1018.47%
2015-12-31	AU$1.29 Million ≈ $916.07K	--

Equity Component Analysis

This analysis shows how different components contribute to Neurotech International Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 5098077200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component	Amount	Percentage
Common Stock	AU$48.91 Million	1655.56%
Other Comprehensive Income	AU$6.20 Million	209.72%
Other Components	AU$1.00	0.00%
Total Equity	AU$2.95 Million	100.00%

Neurotech International Ltd Competitors by Market Cap

The table below lists competitors of Neurotech International Ltd ranked by their market capitalization.

Company	Market Cap
Quantum BioPharma Ltd. NASDAQ:QNTM	$13.99 Million
Golden Land Bhd KLSE:7382	$14.00 Million
Highway 50 Gold Corp V:HWY	$14.01 Million
Altamin Ltd AU:AZI	$14.02 Million
Inter-M Corporation KQ:017250	$13.98 Million
Polyrizon Ltd. Ordinary Shares NASDAQ:PLRZ	$13.98 Million
Les Hôtels de Paris SA PA:HDP	$13.96 Million
Peak Processing Limited AU:PKP	$13.96 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Neurotech International Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 11,898,687 to 2,954,549, a change of -8,944,138 (-75.2%).
Net loss of 10,598,859 reduced equity.
New share issuances of 429,526 increased equity.
Other comprehensive income decreased equity by 524,806.
Other factors increased equity by 1,750,001.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$-10.60 Million	-358.73%
Share Issuances	AU$429.53K	+14.54%
Other Comprehensive Income	AU$-524.81K	-17.76%
Other Changes	AU$1.75 Million	+59.23%
Total Change	AU$-	-75.17%

Book Value vs Market Value Analysis

This analysis compares Neurotech International Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 5.26x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 0.13x to 5.26x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-06-30	AU$0.11	AU$0.02	x
2017-06-30	AU$0.06	AU$0.02	x
2018-06-30	AU$0.04	AU$0.02	x
2019-06-30	AU$0.00	AU$0.02	x
2020-06-30	AU$0.00	AU$0.02	x
2021-06-30	AU$0.01	AU$0.02	x
2022-06-30	AU$0.00	AU$0.02	x
2023-06-30	AU$0.00	AU$0.02	x
2024-06-30	AU$0.01	AU$0.02	x
2025-06-30	AU$0.00	AU$0.02	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Neurotech International Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -358.73%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -433.60%
• Asset Turnover: 0.75x
• Equity Multiplier: 1.10x
Recent ROE (-358.73%) is below the historical average (-265.65%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2015	-64.84%	-390.01%	0.07x	2.54x	AU$-968.88K
2016	-28.95%	-1722.11%	0.01x	2.04x	AU$-2.93 Million
2017	-93.87%	-4565.50%	0.02x	1.15x	AU$-4.46 Million
2018	-94.31%	-13280.17%	0.01x	1.09x	AU$-4.41 Million
2019	-1614.66%	-2468.29%	0.30x	2.19x	AU$-4.83 Million
2020	0.00%	-2214.72%	0.96x	0.00x	AU$-1.65 Million
2021	-192.43%	-3604.58%	0.04x	1.30x	AU$-7.82 Million
2022	-235.12%	-8787.42%	0.02x	1.41x	AU$-3.51 Million
2023	-196.67%	-130759.17%	0.00x	1.34x	AU$-8.19 Million
2024	-42.60%	-258239.99%	0.00x	1.03x	AU$-6.26 Million
2025	-358.73%	-433.60%	0.75x	1.10x	AU$-10.89 Million

Industry Comparison

This section compares Neurotech International Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $5,565,895
Average return on equity (ROE) among peers: -157.98%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Neurotech International Ltd (NTI)	AU$5.88 Million	-64.84%	0.16x	$13.99 Million
Adalta Ltd (1AD)	$7.49 Million	-79.00%	0.24x	$5.41 Million
Algorae Pharmaceuticals Ltd (1AI)	$1.80 Million	-379.70%	1.37x	$14.31 Million
ACRUX Ltd (ACR)	$3.28 Million	-177.05%	1.74x	$4.36 Million
Actinogen Medical Ltd (ACW)	$9.37 Million	-34.06%	0.09x	$78.71 Million
Argenica Therapeutics Ltd (AGN)	$8.31 Million	-49.24%	0.09x	$10.00 Million
Arovella Therapeutics Ltd (ALA)	$10.51 Million	-87.53%	0.53x	$60.73 Million
Anatara Lifesciences Ltd (ANR)	$535.97K	-364.70%	1.14x	$1.92 Million
Alterity Therapeutics Ltd (ATH)	$5.61 Million	-198.54%	0.38x	$108.75 Million
Amplia Therapeutics Ltd (ATX)	$4.87 Million	-107.62%	0.09x	$41.77 Million
Avecho Biotechnology Ltd (AVE)	$3.90 Million	-102.34%	0.23x	$40.65 Million

About Neurotech International Ltd

AU:NTI Australia Biotechnology

Market Cap

$13.99 Million

AU$19.77 Million AUD

Market Cap Rank

#26190 Global

#1199 in Australia

Share Price

AU$0.02

Change (1 day)

-6.25%

52-Week Range

AU$0.01 - AU$0.03

All Time High

AU$0.48